The Role of Interferon in Hepatitis B Therapy.
The Role of Interferon in Hepatitis B Therapy.
复制标题
DOI：
10.1007/s11901-010-0055-1
复制
发表时间：
2010-11
期刊：
影响因子：
--
通讯作者：
Janssen, Harry L A
中科院分区：
文献类型：
--
作者：
Rijckborst, Vincent;Janssen, Harry L A
尽管近年来引入了新的核苷（酸）类似物，但聚乙二醇干扰素仍被当前慢性B型肝炎管理实践指南推荐为潜在的一线治疗选择。由于聚乙二醇干扰素的免疫调节作用，与核苷（酸）类似物相比，聚乙二醇干扰素具有更高的持续停药应答率的优势。约30%的B e抗原（HBeAg）阳性患者和20%的HBeAg阴性患者可持续转变为非活性B表面抗原（HBsAg）携带者状态。最近的研究集中在确定治疗前和治疗中的因素，允许选择可能对聚乙二醇干扰素治疗产生持续应答的患者，以避免与不必要的治疗相关的副作用和费用。未来的研究需要解决特定的病毒学基准是否可以指导有关治疗继续的个体化决策，以及聚乙二醇干扰素与新的有效核苷（酸）类似物联合是否可以改善治疗结果。
Despite the introduction of new nucleos(t)ide analogues in recent years, peginterferon is still recommended as a potential first-line treatment option by current practice guidelines for the management of chronic hepatitis B. Peginterferon offers the advantage of higher sustained off-treatment response rates compared to nucleos(t)ide analogues because of its immunomodulatory effects. Sustained transition to the inactive hepatitis B surface antigen (HBsAg) carrier state can be achieved in about 30% of hepatitis B e antigen (HBeAg)–positive patients and 20% of HBeAg-negative patients. Recent studies have focused on identification of pretreatment and on-treatment factors that allow the selection of patients who are likely to achieve a sustained response to peginterferon therapy in order to avoid the side-effects and costs associated with unnecessary treatment. Future studies need to address whether specific virologic benchmarks can guide individualized decisions concerning therapy continuation and whether peginterferon combined with new potent nucleos(t)ide analogues improves treatment outcomes.